Clinical Trials Logo

Arsenic Trioxide clinical trials

View clinical trials related to Arsenic Trioxide.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05682131 Recruiting - Childhood ALL Clinical Trials

South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol

SCCCG-R-ALL
Start date: September 27, 2022
Phase: Phase 4
Study type: Interventional

In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%. A number of in vitro studies have shown that arsenic trioxide (ATO) can selectively inhibit the growth and induce apoptosis in a variety of leukemia cell lines, suggesting that ATO as a synergist combined with other common chemotherapy drugs may provide a new target for the treatment of relapsed ALL. Realgar Indigo naturalis formula is a compound traditional Chinese medicine preparation developed in China. The main component of realgar is arsenic tetrasulfide (As4S4), which can produce similar pharmacological effects to ATO. Based on the R3 protocol, this study plans to perform a double-blind randomized controlled trial, and to randomly combine compound Huangdai tablets with compound Huangdai tablets in the treatment of intermediate and high risk ALL children, in order to improve the MRD negative rate after induction therapy in this group of children, which may provide a new method for the clinical treatment of relapsed ALL.

NCT ID: NCT04695223 Recruiting - Refractory Cancer Clinical Trials

Arsenic Trioxide for Structural p53 Mutations

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with thermostability and transcriptional activity. Under Vivo and Vitro experiments, arsenic trioxide could reactivate mutated p53 to inhibit tumor. This trial aimed to explore the efficacy and safety of arsenic trioxide in refractory cancer patients with structural p53 mutations.